Skip to main content

Table 4 Weighted mean estimates for the proportion of missing/unknown values on case report and medical record

From: Assessing the validity of tuberculosis surveillance data in California

#* Report of Verified Case of Tuberculosis (RVCT) Variable RVCT Missing/Unknown % (95% CI) Public Health Medical Record Missing/Unknown % (95% CI)
  DEMOGRAPHIC
1 Sex 0.0 - 0.0 -
2 Race 0.0 - 1.3 (0.7, 2.6)
3 Ethnicity 0.0 - 1.4 (0.7, 2.6)
  Country of origin     
4    U.S.-born 0.6 (0.2, 1.5) 2.7 (1.7, 4.2)
5    Other country of origin 0.0 - 0.1 (0.1, 0.1)
6 Occupation 8.2 (6.3, 10.6) 23.6 (20.4, 27.1)
7 Resident of long-term care facility at diagnosis 0.2 (0.1, 0.4) 7.6 (5.8, 9.9)
8 Resident of correctional facility at diagnosis 0.1 (0.0, 0.3) 6.7 (5.1, 8.9)
  SOCIAL/BEHAVIORAL RISK FACTORS
9 Homeless within past 1–2 years§ 1.9 (1.1, 3.2) 63.8 (59.9, 67.5)
10 Injecting drug user within past year 8.0 (6.2, 10.2) 22.1 (19.1, 25.4)
11 Non-injecting drug user within past year 7.8 (6.0, 10.0) 23.4 (20.3, 26.8)
12 Excess alcohol use within past year 7.6 (5.9, 9.8) 24.1 (21.0, 27.6)
  DIAGNOSTIC AND CLINICAL
13 Previous TB 0.0 - 19.7 (16.8, 22.9)
14 Site of disease 0.0 - 0.0 -
15 Sputum smear|| 4.9 (3.4, 7.2) 6.0 (4.2, 8.7)
16 Sputum culture|| 15.1 (12.1, 18.7) 14.4 (11.5, 17.8)
17 Smear of tissue/body fluids (non-sputum)|| 0.6 (0.3, 1.5) 78.9 (75.6, 82.0)
18    Tissue/body fluid type (non-sputum)* * 0.0 - 0.0 -
19 Culture of tissue/other body fluid (non-sputum)|| 0.3 (0.1, 1.1) 63.6 (59.8, 67.2)
20    Tissue/body fluid type (non-sputum) * * 0.0 - 0.0 -
  Chest x-ray results     
21    Abnormal/normal|| 0.6 (0.3, 1.5) 8.7 (6.8, 11.2)
22    If abnormal: cavitary/non-cavitary** 0.1 (0.0, 0.4) 0.0 -
23    If abnormal: stable/worsening/improving** 68.9 (64.8, 72.7) 45.3 (40.9, 49.7)
24 Initial susceptibility testing done 0.0 - 1.7 (0.9, 3.1)
  Results of initial susceptibility testing, if done††     
25    Isoniazid|| 0.0 - 3.1 (2.0, 4.9)
26    Rifampin|| 0.7 (0.3, 1.8) 21.2 (18.1, 24.5)
27    Pyrazinamide|| 0.0 - 3.1 (2.0, 4.9)
28    Ethambutol|| 0.0 - 4.1 (2.8, 6.0)
29    Streptomycin|| 0.0 - 2.9 (1.8, 4.6)
  TREATMENT AND CASE MANAGEMENT
  Initial treatment regimen     
30    Isoniazid 0.0 - 0.0 -
31    Rifampin 0.0 - 0.0 -
32    Pyrazinamide 0.1 (0.0, 0.3) 0.0 -
33    Ethambutol 0.0 - 0.0 -
34    Streptomycin 0.1 (0.0, 0.3) 0.0 -
35 Sputum culture conversion, if ever sputum culture positive** 1.6 (0.7, 3.5) 0.0 -
36 Reason therapy stopped 0.7 (0.3, 1.5) 0.0 -
37 Provider type 0.2 (0.0, 1.3) 0.0 -
38 Therapy administration 3.5 (2.4, 5.2) 0.0 -
39 Final susceptibility testing done‡‡ 0.0 -   
  Results of final susceptibility testing, if done‡‡     
40    Isoniazid||‡‡ 0.0 - 5.7 (1.5, 19.6)
41    Rifampin||‡‡ 0.0 - 5.7 (1.5, 19.6)
42    Pyrazinamide||‡‡ 5.1 (0.9, 25.2) 11.9 (4.9, 26.2)
43    Ethambutol||†† 0.0 - 6.4 (1.9, 19.3)
44    Streptomycin||‡‡ 0.0 - 9.8 (3.3, 25.4)
  DATES
45 TB case report date 0.0 - 5.7 (4.1, 7.8)
46 Date of birth 0.0 - 0.1 (0.0, 0.3)
47 Date arrived in United States (foreign-born cases)** 9.2 (7.0, 12.1) 15.1 (12.1, 18.6)
48 Treatment start date 0.0 - 0.0 -
49 Date specimen collected for initial drug susceptibility testing** 0.0 - 2.1 (1.2, 3.7)
50 Date specimen collected on initially positive sputum culture** 0.0 - 0.0 -
51 Date specimen collected on first consistently negative sputum culture** 1.4 (0.5, 3.8) 0.2 (0.2, 0.2)
52 Date TB treatment stopped 0.2 (0.2, 0.2) 0.0 -
53 Date specimen collected for final drug susceptibility testing††‡‡ 5.1 (0.9, 25.2) 9.8 (3.3, 25.4)
  1. Note: All results are presented as survey-weighted mean estimates for the statewide cohort from which the sample was drawn.
  2. * Variable number (see Table 1)
  3. † Confidence Interval
  4. ‡ With an estimate of 0.0% missing/unknown, a confidence interval was not determined
  5. § RVCT defines homeless within 1 year of diagnosis; medical record review defined homeless within 2 years of diagnosis
  6. || 'Not done' on RVCT excluded
  7. ** For nine RVCT variables, values are expected depending on the value of another variable (e.g., a value for type of chest x-ray abnormality or status of chest x-ray is expected only if chest x-ray results are abnormal). For these nine variables, we restricted our estimate of missing/unknown values to instances in which a subsequent value was expected, but missing, and did not count expected absent values as 'missing'.
  8. †† As a result of a very small number of second-line drug susceptibility test results, these results are not presented, either for initial or final drug susceptibility testing.
  9. ‡‡ Based on small number of cases with final susceptibility testing performed; therefore estimate is subject to considerable instability